Merck Sharp & Dohme China (MSD China)

This sponsor has funded 6 studies across 1 countries.

PAS funded by this sponsor.
EU PAS ID Status RMP requirement Title Protocol uploaded Results uploaded
45840 Ongoing Not included in RMP A multicenter, prospective, cohort study to investigate the incidence and clinical management of CMV infection in adult patients with hematological... No No
47111 Planned Not included in RMP Survey on Chinese urologists of BCG utilization in Chinese NMIBC patients No No
48393 Ongoing Not included in RMP China Real World Study on Patient Baseline Characteristics and Treatment Pattern of Endometrial Cancer (PEC) No No
48396 Ongoing Not included in RMP Clinicopathological feature and treatment pattern of esophageal cancers in China: the CHANNEL study No No
48399 Planned Not included in RMP A Prospectively Observational Study to Investigate the Epidemiology and Patient Profile of Chronic Cough in Chinese Respiratory Outpatient Department No No
103485 Planned Not included in RMP Assessment of Disease Feature and Treatment Pattern of Locally Advanced, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma in China... No No

PAS by Risk Management Plan (RMP) requirement

Merck Sharp & Dohme China (MSD China)

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.